Related Experiment Video
Updated: Sep 10, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Acebutolol and hydrochlorothiazide in essential hypertension
Insights
Acebutolol (ABL) effectively lowers blood pressure in patients with essential hypertension. Unlike hydrochlorothiazide (HCT), ABL also reduces heart rate and tension-time index without adverse effects on potassium or uric acid.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Essential hypertension is a common condition.
- Peripheral renin activity can influence treatment choices.
Purpose of the Study:
- To compare the efficacy and effects of Acebutolol (ABL) and hydrochlorothiazide (HCT) in patients with mild to moderate essential hypertension and low or normal peripheral renin activity.
Main Methods:
- Patients with mild to moderate essential hypertension and low/normal renin activity were treated with either ABL or HCT.
- Blood pressure, heart rate, and peripheral renin activity were monitored.
- Adverse effects on serum potassium and uric acid were assessed.
Main Results:
- Both ABL and HCT reduced supine blood pressure effectively.
- ABL decreased heart rate, while HCT increased it.
- Tension-time indices were lower with ABL due to reduced heart rate.
- ABL did not negatively impact serum potassium or uric acid levels.
- Peripheral renin activity increased with HCT but remained stable or decreased with ABL.
Conclusions:
- Acebutolol is as effective as hydrochlorothiazide in lowering blood pressure for this patient group.
- ABL offers additional benefits by reducing heart rate and tension-time index.
- ABL presents a favorable safety profile regarding serum electrolytes and uric acid.
Abstract:
Acebutolol (ABL) and hydrochlorothiazide (HCT) were compared in patients with mild to moderate essential hypertension and low or normal peripheral renin activity. ABL reduced mean supine blood pressure from 151/97 to 140/87 mm Hg and HCT reduced the mean supine blood pressure from 153/98 to 143/92 mm Hg. ABL reduced heart rate from 73 to 67 beats/min; during HCT therapy it rose from 74 to 77 beats/min. Although the same proportion of patients achieved normal diastolic pressures with ABL (11/19) and with HCT (10/19), tension-time indices were lower during ABL than during HCT therapy. The average daily dose was 621 mg of ABL and 168 mg of HCT. Stimulated peripheral renin activity increased with HCT and was the same or lower with ABL. ABL did not induce adverse effects on serum potassium or uric acid. ABL was as effective in lowering blood pressure HCT but induced larger reductions in tension-time index as a result of the lowerered heart rate.
Related Concept Videos
Antihypertensive Drugs: Action of Diuretics
Antihypertensive Drugs: Thiazide-Class Diuretics
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
